Latest From Nestle SA
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.
Allergan is selling its Crohn’s disease and ulcerative colitis drug brazikumab back to AstraZeneca to satisfy regulators ahead of its link-up with AbbVie, essentially giving the asset to the UK major for free.
Else Nutrition will be one of the first companies to market baby and toddler formula and a children’s beverage without dairy or soy while containing a few core ingredients, says CEO Hamutal Yitzhak. Products will debut in North America and Europe in 2020.
A group of investors has bought Nestlé Skin Health, renamed it Galderma to capitalize on its legacy in dermatology and put M&A veteran, former Shire CEO Flemming Ornskov, at its helm.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Nestle Health Science SA
- Nestle HealthCare Nutrition
- Nestle Skin Health SA
- Nestle USA Inc.
- Novartis Medical Nutrition
- Owen-Galderma Laboratories Inc.
- Summit Autonomous Inc.
- Senior Management
Mark Schneider, CEO
François-Xavier Roger, EVP, CFO
Stefan Palzer, EVP, CTO
- Contact Info
Phone: (41) 21 924 2111
avenue Nestlé 55
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.